To testify at criminal or disciplinary proceedings and to give testimony relative to investigations. To assist local police in investigations.

To investigate drug charges, criminal charges, violations of law or department policies by Department of Corrections personnel and/or any other party conducting activity or business for or with the DOC. To be charged with the duties of conducting investigations into such incidents in which the Department of Corrections is a party of interest or maybe a party of interest. To work with the Rhode Island State Police and federal and local law enforcement agencies in collecting and disseminating information regarding violations of Rhode Island State laws and departmental policies as it relates to staff or other misconduct or any other illegal, illicit or improper activity that that affects the operation of the department. To be responsible for conducting internal investigations regarding staff or other misconduct on or off duty to include the trafficking of narcotics and substance abuse within the Rhode Island Department of Corrections and its facilities. SUPERVISION RECEIVED: Works under the administrative direction of the Director and the Chief Inspector with latitude to conduct investigation into staff or other misconduct, or any other illegal improper or illicit activity to include narcotic violations within the scope of the Department of Corrections in conformity with Rhode Island State laws and departmental polices. In most cases, there were similarities in questions asked (top 5 ranking) and their geographical source for sales representative triage versus customers directly.Ĭompliance medical information off-label sales representatives unsolicited.GENERAL STATEMENT OF DUTIES: To be responsible for conducting internal investigations for Rhode Island Department of Corrections (RIDOC) regarding misconduct of staff, or any other party that conducts activities or business within) (RIDOC) -to include inmates, vendors, visitors or volunteers, for the investigation of trafficking of narcotics and substance abuse or any other illegal, improper or illicit activity within the Rhode Island Department of Corrections and its facilities to work with the Rhode Island State Police and federal and local law enforcement agencies in collecting and disseminating information regarding violations of staff or other misconduct and Rhode Island State laws and departmental policies governing the control of substance abuse as it effects the operation of the Department and to do related work as required. 001) for the rate of 4.8% to 8.1% observed collectively for all customer sources. For the set of sales representative triage submissions in 20, the 'off-label indications/uses' category accounted for 15.3% to 20.5%, respectively, and was statistically significant ( P <.

Questions related to 'off-label indications/uses' (ie, compliance topic of most interest to regulatory agencies) accounted for 5.8% of all inquiries and were almost equally distributed in number between sales representative triage and HCW direct calls to the PIMID. In an analysis of all inquires (n = 20,213) received over a 2-year period (2010-2011), it was observed that inquires submitted by sales representatives after unsolicited health care worker (HCW) requests accounted for only 14.8% of requests overall. By tagging all response documents with 'compliance topic' codes that reflect the type of off-label inquiry (eg, unapproved indications/uses, more detailed or extended data, adverse events, etc) and specifically tracking for the inquiry source route, our PIMID was able to analyze and compare customer inquiries including those triaged by sales representatives.

Especially of interest are unsolicited off-label inquiries triaged via sales representatives. Pharmaceutical industry medical information departments (PIMIDs) are encouraged to monitor and report on patterns of activity, including the source and frequency and types of off-label inquiries received. Unsolicited inquiries for off-label medical/product information are the focus of compliance monitoring programs as described in regulatory guidance published by the US Office of the Inspector General (OIG) and the US Food and Drug Administration (FDA).

Ridoc office of inspections